ProCE Banner Activity

Predictive Biomarkers for Targeted Therapies in Advanced NSCLC: EGFR mutations, EGFR Exon 20 Insertions, and HER2 Mutations

Slideset Download
Download these slides from a live CCO Webinar for an overview of the latest clinical data informing optimal use of EGFR, EGFR ex20ins, and HER2 biomarkers to guide therapeutic decisions in advanced NSCLC, including updates from recent annual clinical oncology meetings.

Released: June 28, 2021

Expiration: June 27, 2022

Share

Faculty

Suresh S. Ramalingam

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Lecia V. Sequist

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts